Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins
Maurizio Benucci,1 Francesca Li Gobbi,1 Francesca Meacci,2 Mariangela Manfredi,2 Maria Infantino,2 Maurizio Severino,3 Sergio Testi,3 Piercarlo Sarzi-Puttini,4 Cristian Ricci,5 Fabiola Atzeni4 1Rheumatology Unit, 2Immunology and Allergology Laboratory Unit, 3Allergy and Clinical Immunology Unit, Nuovo Ospedale S Giovanni di Dio, Florence, Italy; 4Rheumatology Unit, L Sacco University Hospital, Milan, Italy; 5Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany Abstract: Although anti-TNF drugs have changed the clinical course of rheumatoid arthritis (RA), survival rates and resi...
Source: Biologics: Targets and Therapy - February 16, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Antibodies against TNF-blocking agents
Benucci M, Li Gobbi F , Meacci F, Manfredi M, Infantino M, Severino M, Testi S, Sarzi-Puttini P, Ricci C, Atzeni F (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - February 16, 2015 Category: Biochemistry Source Type: research
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antib...
Source: Biologics: Targets and Therapy - February 16, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Obinutuzumab in the treatment of therapy naive CLL patients
Cerquozzi S, Owen C (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - February 15, 2015 Category: Biochemistry Source Type: research
Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
Catalin O Codreanu,1 Nemanja Damjanov2 1Rheumatology Department, Center of Rheumatic Diseases, Bucharest, Romania; 2Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, SerbiaAbstract: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA). Biologics selectively target components of the immune system, resulting in better disease control. However, the growing use of biologics in RA has increased safety concerns among rheumatologists. Randomized controlled trials (RCTs) and registries are the most reliable sources of clinical safety data. A...
Source: Biologics: Targets and Therapy - January 26, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Safety of biologics in RA
Codreanu C, Damjanov N (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - January 26, 2015 Category: Biochemistry Source Type: research
Multikinase inhibitors use in differentiated thyroid carcinoma
Sina Jasim,1,* Levent Ozsari,2,* Mouhammed Amir Habra2 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA; 2Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA *These authors contributed equally in this work Abstract: Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requir...
Source: Biologics: Targets and Therapy - December 3, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Multikinase inhibitors and differentiated thyroid carcinoma
Jasim S, Ozsari L, Habra MA (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - December 3, 2014 Category: Biochemistry Source Type: research
Inactivation of chromatin remodeling factors sensitizes cells to selective cytotoxic stress
Miles D Freeman, Tryphon Mazu, Jana S Miles, Selina Darling-Reed, Hernan Flores-Rozas College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA Abstract: The SWI/SNF chromatin-remodeling complex plays an essential role in several cellular processes including cell proliferation, differentiation, and DNA repair. Loss of normal function of the SWI/SNF complex because of mutations in its subunits correlates with tumorigenesis in humans. For many of these cancers, cytotoxic chemotherapy is the primary, and sometimes the only, therapeutic alternative. Among the antineoplastic agents, anth...
Source: Biologics: Targets and Therapy - November 14, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Inactivation of chromatin remodeling factors
Freeman MD, Mazu T, Miles JS, Darling-Reed S, Flores-Rozas H (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - November 13, 2014 Category: Biochemistry Source Type: research
